Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) is a clinical-stage biopharmaceutical company that specializes in developing innovative cell and gene therapies aimed at curing certain cancers and rare diseases. The company's core focus is on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with unmet medical needs. Poseida's pipeline includes autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates, initially targeting hematological malignancies and solid tumors.
Poseida boasts best-in-class genome engineering capabilities, utilizing proprietary tools like the piggyBac™ DNA modification system, nextGEN™ CRISPR, XTN™ TALEN, and the footprint-free™ gene editing system. These tools are virus-free and offer surgical precision in gene editing, enabling the development of highly effective therapies.
Recent achievements include significant advancements in the company's lead program, P-BCMA-ALLO1, a novel BCMA-targeted allogeneic CAR-T therapy for treating relapsed/refractory multiple myeloma (RRMM). The FDA recently granted Orphan Drug Designation for P-BCMA-ALLO1, underscoring its potential to meet high unmet medical needs. Poseida is investigating this therapy in collaboration with Roche, with promising preliminary data presented at major scientific conferences.
In addition to its focus on cancer, Poseida is also advancing genetic medicines for rare diseases. The company has highlighted progress in its gene therapy pipeline, especially for conditions like Hereditary Angioedema and Hemophilia A. These programs employ fully non-viral approaches, leveraging Poseida's advanced genetic engineering and delivery platforms.
Poseida has formed strategic collaborations with industry giants like Janssen and Roche, enhancing its capacity to bring innovative therapies to market. The company also recently entered into a research collaboration with Xyphos Biosciences, a subsidiary of Astellas, to develop novel convertibleCAR® programs targeting solid tumors.
Financially, Poseida reported revenues of $28.1 million for Q1 2024, a substantial increase from the previous year, primarily driven by collaborations with Astellas and Roche. With a strong cash position and additional funding from strategic partnerships, Poseida is well-positioned to advance its pipeline and achieve key milestones in 2024 and beyond.
Learn more about Poseida Therapeutics and its groundbreaking work by visiting www.poseida.com and connecting with the company on X and LinkedIn.
On March 1, 2023, Poseida Therapeutics (Nasdaq: PSTX) announced the addition of five new members to its Gene Therapy Scientific Advisory Board (SAB), enhancing its expertise in developing innovative gene therapies. The new SAB members include top researchers from global institutions, such as Ian Alexander and Mark Kay. The appointment aims to strengthen the company's gene therapy initiatives targeting rare and life-threatening diseases, including Ornithine Transcarbamylase Deficiency and Hemophilia A. With proprietary technologies like the Cas-CLOVER™ gene editing system, Poseida seeks to pioneer targeted gene therapies that can potentially serve as single treatment cures for these conditions.
Poseida Therapeutics (Nasdaq: PSTX) hosted its third annual Virtual R&D Day on February 22, 2023, showcasing advancements in its clinical and preclinical pipeline. Key presentations included the announcement of P-PAH-101, a new liver-directed gene therapy for Phenylketonuria (PKU), partnered with Takeda. The company highlighted its Super piggyBac platform, improving site-specific editing, and shared progress in its allogeneic CAR-T cell therapy programs targeting cancers. The event featured industry experts and emphasized Poseida's innovative technologies aimed at treating cancer and rare diseases.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced that its CEO, Mark Gergen, will participate in a fireside chat during the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 11:00 AM ET. The event focuses on advancements in cell and gene therapies for cancer and rare diseases. Investors can access a live webcast of the presentation on Poseida's website, with a replay available for 90 days post-event. Poseida is recognized for its proprietary genetic editing platforms aimed at improving patient outcomes in oncology.
Poseida Therapeutics (Nasdaq: PSTX) has announced its third-annual virtual R&D Day, scheduled for February 22, 2023, from 10:00 am to 1:30 pm ET. The event will feature presentations by executive leadership and scientists, focusing on advancements in cell and gene therapy, including proprietary genetic engineering platforms and CAR-T programs. Special guest speakers include George M. Church, Madhu Natarajan, and Christine Brown. Registration and access to the live webcast can be found on Poseida's website, with a replay available for 90 days post-event.
Poseida is dedicated to developing innovative therapies for cancer and rare diseases.
Poseida Therapeutics, Inc. (NASDAQ: PSTX) announced that Dr. Eric Ostertag will retire from the Board of Directors effective February 3, 2023, but will continue as a consultant. Dr. Ostertag, who founded Poseida eight years ago, has transitioned through various leadership roles, including CEO and Executive Chairman. Under his leadership, the company has grown significantly, completed its IPO in 2020, and received FDA clearance for four IND applications. Poseida aims to advance innovative cell and gene therapies for cancer and rare diseases, leveraging its proprietary technologies and established collaborations with Roche and Takeda.
Poseida Therapeutics, Inc. (PSTX) announced promising preclinical data for its P-FVIII-101 gene therapy aimed at treating Hemophilia A, presented at the ASH Annual Meeting. The non-viral, liver-directed therapy demonstrated sustained normalization of human FVIII activity in animal models after a single dose. The results suggest a potential functional cure and a more durable treatment option, particularly for juvenile patients. Partnering with Takeda, Poseida plans to advance this promising program towards an Investigational New Drug application.
Poseida Therapeutics (PSTX) announced early results from Phase 1 trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1, both demonstrating safety and tolerability without dose-limiting toxicities. P-MUC1C-ALLO1 showed an objective partial response in a breast cancer patient. Meanwhile, P-BCMA-ALLO1 achieved a 50% overall response rate among heavily pre-treated multiple myeloma patients. Both trials are designed to explore further patient enrollments and dose optimization strategies, with updates expected in 2023.
Poseida Therapeutics, Inc. (PSTX) entered a strategic collaboration with Roche for allogeneic CAR-T therapies, securing a $110 million upfront payment and achieving a $35 million milestone. In Q3 2022, Poseida reported revenues of $116.3 million, marking a significant increase from 2021, while R&D expenses rose to $35.1 million due to increased headcount. Despite this, net income was $70.4 million, a notable improvement from a loss the previous year. The company’s cash reserves stand at $279 million, expected to extend its operations into mid-2024.
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company, announced participation in two investor conferences. The Stifel 2022 Healthcare Conference is scheduled for November 16, 2022, at 10:20 am ET, while the Piper Sandler 34th Annual Healthcare Conference will take place on November 30, 2022, at 11:30 am ET. Webcasts will be available on Poseida's website, with replays accessible for 90 days post-event. Poseida focuses on innovative cell and gene therapeutics utilizing proprietary genetic engineering platforms.
Poseida Therapeutics announced that preclinical data for its gene therapy P-FVIII-101 will be presented at the 64th ASH Annual Meeting on December 11, 2022. The therapy targets Hemophilia A and uses a non-viral delivery system, showing sustained Factor VIII activity for over six months in mouse models. This presentation illustrates the potential for P-FVIII-101 to provide a durable treatment solution. The P-FVIII-101 program is in collaboration with Takeda, highlighting Poseida’s innovative approach to gene therapy.
FAQ
What is the current stock price of Poseida Therapeutics (PSTX)?
What is the market cap of Poseida Therapeutics (PSTX)?
What is Poseida Therapeutics, Inc.?
What are Poseida's core technologies?
What is P-BCMA-ALLO1?
Who are Poseida's strategic partners?
What diseases is Poseida targeting with its gene therapies?
What recent financial achievements has Poseida reported?
What is Poseida's approach to gene editing?
How can I learn more about Poseida Therapeutics?
What is the significance of the Orphan Drug Designation for P-BCMA-ALLO1?
What are Poseida's future plans?
